What is Lee's Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) %?
Lee's Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Dec. 2024 was HK$744 Mil.
Lee's Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$112 Mil. Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2024 was 15.06%.
The historical rank and industry rank for Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
HKSE:00950'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.84 Med: 7.44 Max: 270.72
Current: 15.29
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Lee's Pharmaceutical Holdings was 270.72%. The lowest was 2.84%. And the median was 7.44%.
HKSE:00950's Earnings Yield (Joel Greenblatt) % is ranked better than 93.25% of 1022
companies
in the Drug Manufacturers industry
Industry Median: 2.94
vs HKSE:00950: 15.29
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Lee's Pharmaceutical Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was -10.82%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Lee's Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Lee's Pharmaceutical Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2024 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Lee's Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:00950 has been successfully added to your 